

# Minglei Zhuo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8373100/publications.pdf>

Version: 2024-02-01

55  
papers

1,965  
citations

430754

18  
h-index

254106

43  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21083-21088.	3.3	396
2	Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3077-3083.	0.8	188
3	Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. PLoS ONE, 2014, 9, e110780.	1.1	121
4	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. Cancer Research, 2019, 79, 7-20.	0.4	113
5	Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 1324-1330.	3.2	100
6	Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e54170.	1.1	89
7	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
8	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget, 2016, 7, 20810-20824.	0.8	73
9	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. Clinical Cancer Research, 2019, 25, 5049-5060.	3.2	66
10	EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer, 2010, 67, 343-347.	0.9	52
11	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Journal of Thoracic Oncology, 2017, 12, 1766-1778.	0.5	51
12	Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. Journal of Hematology and Oncology, 2015, 8, 127.	6.9	45
13	EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer. Oncology, 2012, 83, 248-256.	0.9	43
14	DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 80.	3.5	39
15	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387.	0.5	39
16	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer, 2012, 3, 334-340.	0.8	36
17	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. Cancer Biomarkers, 2018, 22, 467-476.	0.8	33
18	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. BMC Cancer, 2020, 20, 666.	1.1	22

#	ARTICLE	IF	CITATIONS
19	Patients harboring epidermal growth factor receptor (<sc>EGFR</sc> double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with <sc>EGFR</sc>-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2014, 5, 126-132.	0.8	21
20	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , 2019, 10, 2088-2095.	0.8	20
21	ER $\alpha$ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. <i>Scientific Reports</i> , 2015, 5, 11392.	1.6	19
22	Programmed cell death ligand 1 (<sc>PD-L</sc>1) expression and fibroblast growth factor receptor 1 (<sc>FGFR</sc>1) amplification in stage <sc>III/IV</sc> lung squamous cell carcinoma (<sc>SQC</sc>). <i>Thoracic Cancer</i> , 2017, 8, 73-79.	0.8	17
23	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020, 10, 626.	1.3	17
24	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021, 10, 981-994.	1.3	17
25	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
26	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1584.	1.3	15
27	Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 2425-2431.	0.8	14
28	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019, 10, 459-471.	0.8	14
29	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 553-560.	0.7	13
30	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , 2020, 145, 140-143.	0.9	13
31	Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. <i>Thoracic Cancer</i> , 2017, 8, 138-146.	0.8	12
32	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019, 10, 1193-1202.	0.8	12
33	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020, 20, 793.	1.1	12
34	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2081-2087.	0.8	11
35	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e154-e159.	0.7	11
36	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2020, 10, 574752.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Epidermal growth factor receptor variant <i>EGFR</i> mutation in Chinese patients with squamous cell cancer of the lung. <i>Thoracic Cancer</i> , 2015, 6, 319-326.	0.8	10
38	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	0.8	10
39	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019, 10, 1788-1797.	0.8	10
40	The prevalence and real-world therapeutic analysis of Chinese patients with <i>KRAS</i> mutant Non-small Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.	1.3	10
41	Co-Occurring Alterations of <i>ERBB2</i> Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. <i>Frontiers in Oncology</i> , 2020, 10, 729.	1.3	9
42	Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 2660-2667.	0.8	9
43	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 1149-1159.	0.8	8
44	Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e51021.	1.1	7
45	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1137.	1.3	7
46	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma: A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 639892.	1.6	7
47	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 291-297.	0.8	5
48	Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. <i>BMC Cancer</i> , 2021, 21, 1107.	1.1	5
49	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage IIIA non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2021, 13, 1799-1812.	0.6	4
50	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021, 13, 1813-1821.	0.6	3
51	A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, e21053-e21053.	0.8	1
52	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 12-8.	0.7	1
53	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020, 20, 590.	1.8	0
54	Relationship between loss-of-function mutation of the stromal antigen 2 gene and treatment in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, e20509-e20509.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Co-mutation features in treatment-naïve EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e21616-e21616.	0.8	0